Healthcare Services

GM1 Gangliosidosis Industry Expansion Forecast Showing Market Size of $0.95 Billion by 2030 at 10.8% CAGR

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The GM1 Gangliosidosis Market Over The 2026–2030 Period?

The market for gm1 gangliosidosis has experienced rapid expansion in recent years. It is projected to increase from $0.57 billion in 2025 to $0.63 billion in 2026, at a compound annual growth rate (CAGR) of 11.1%. This historical growth can be attributed to elements such as rare disease research initiatives, the identification of enzyme deficiencies, advancements in genetic diagnostics, hospital-based pediatric care, and early clinical studies.

The gm1 gangliosidosis market is projected to experience substantial expansion over the coming years. By 2030, its valuation is anticipated to reach $0.96 billion, demonstrating a compound annual growth rate (CAGR) of 10.8%. This anticipated growth during the forecast period is primarily driven by factors such as the expansion of the gene therapy pipeline, incentives for orphan drugs, advancements in diagnostic screening, heightened patient advocacy, and increased biotechnology funding. Key developments expected within the forecast timeframe encompass an escalating emphasis on developing drugs for rare diseases, intensified research into gene therapy, broader adoption of enzyme replacement therapies, wider implementation of newborn genetic screening, and a surge in clinical trial undertakings.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp

Which Economic Or Industry Drivers Are Impacting The GM1 Gangliosidosis Market?

The expanding integration of gene therapy is projected to stimulate the growth of the GM1 gangliosidosis market moving forward. Gene therapy is a medical intervention that involves altering or replacing genes within a person’s cells to manage or prevent diseases. The increasing uptake of gene therapy is propelled by advances in genetic research, improved patient outcomes for conditions that were previously untreatable, and strengthening regulatory support for innovative treatments. For GM1 gangliosidosis, gene therapy works by delivering a functional copy of the defective gene (GLB1) to patient cells, aiming to restore ß-galactosidase enzyme activity and reduce the buildup of toxic substrates. For example, in January 2024, the American Society of Gene & Cell Therapy, a US-based organization, reported that in Q4 2023, the number of gene therapies in Phase III increased by 10% compared to the prior quarter, marking the first rise since Q3 2022. Therefore, the growing adoption of gene therapy is driving the expansion of the GM1 gangliosidosis market.

How Is The GM1 Gangliosidosis Market Segmented Across Key Categories?

The gm1 gangliosidosis market covered in this report is segmented –

1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis

2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy

3) By End-User: Research Institutes, Hospitals, Other End-Users

Subsegments:

1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset

2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset

3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset

Which Trends Are Impacting The Growth Of The GM1 Gangliosidosis Market?

Leading companies active in the GM1 gangliosidosis market are prioritizing strategic alliances to secure their market presence. Strategic partnerships are essential for advancing gene therapy development by integrating expertise, resources, and technologies to accelerate research, clinical trials, and commercialization. For example, in October 2024, GEMMA Biotherapeutics Inc., a US-based biotechnology company, formed a partnership with the Oswaldo Cruz Foundation (Fiocruz), a Brazil-based health research institution, to develop gene therapies for rare diseases, including GM1 gangliosidosis. The agreement entails up to $100 million in funding from Fiocruz for clinical research and manufacturing, intending to make these advanced therapies accessible through Brazil’s public healthcare system. This collaboration underscores technology transfer and aims to democratize access to treatments that were previously restricted to higher-income populations.

Who Are The Dominant Players Shaping The GM1 Gangliosidosis Market Landscape?

Major companies operating in the gm1 gangliosidosis market are Pfizer Inc, Sanofi S A, Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc, CRISPR Therapeutics AG, REGENXBIO Inc, Passage Bio Inc, Orchard Therapeutics plc, AVROBIO Inc, uniQure N V, Lysogene S A, Sio Gene Therapies Inc, bluebird bio Inc, Axovant Gene Therapies Ltd, Lysosomal Therapeutics Inc, Encoded Therapeutics Inc, Abeona Therapeutics Inc, JCR Pharmaceuticals Co Ltd, Sangamo Therapeutics Inc

Read the full gm1 gangliosidosis market report here:

https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report

What Are The Top-Performing Regions Within The GM1 Gangliosidosis Market?

North America was the largest region in the GM1 gangliosidosis market in 2025. The regions covered in the gm1 gangliosidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored GM1 Gangliosidosis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21194&type=smp

Browse Through More Reports Similar to the Global GM1 Gangliosidosis Market 2026, By The Business Research Company

Glycomic Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Glycol Global Market Report

https://www.thebusinessresearchcompany.com/report/glycol-global-market-report

Glyphosate Global Market Report

https://www.thebusinessresearchcompany.com/report/glyphosate-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795